Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prior Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7,054 result(s) found for: Prior Placebo. Displaying page 285 of 353.
    «« First « Previous 281  282  283  284  285  286  287  288  289  Next» Last»»
    EudraCT Number: 2019-004878-26 Sponsor Protocol Number: IM011-127 Start Date*: 2021-01-05
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis.
    Medical condition: Moderate to Severe Ulcerative Colitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001247-27 Sponsor Protocol Number: 202100166 Start Date*: 2021-09-30
    Sponsor Name:University Medical Center Groningen
    Full Title: SeMaglutide and Albuminuria Reduction Trial in obese individuals without diabetes
    Medical condition: Overweight and obese individuals at high risk of chronic kidney disease progression.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003666-13 Sponsor Protocol Number: VAC89220HPX3002 Start Date*: 2019-10-15
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1...
    Medical condition: Prevention of HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Restarted) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000241-39 Sponsor Protocol Number: ID-054-304 Start Date*: 2018-08-27
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to...
    Medical condition: Aneurysmal Subarachnoid Hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10039330 Ruptured cerebral aneurysm PT
    21.1 10029205 - Nervous system disorders 10042316 Subarachnoid haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) SE (Completed) FR (Completed) CZ (Completed) BE (Completed) DK (Completed) HU (Completed) AT (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000670-28 Sponsor Protocol Number: CLTP001A12201 Start Date*: 2022-04-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, participant- and investigator-blinded, placebo-controlled study to investigate efficacy, safety and tolerability of LTP001 in participants with pulmonary arterial hypertension
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001637-18 Sponsor Protocol Number: CKI- 302 Start Date*: 2006-11-13
    Sponsor Name:NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)
    Full Title: A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart f...
    Medical condition: Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) CZ (Completed) BE (Completed) DK (Prematurely Ended) GB (Completed) HU (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002261-19 Sponsor Protocol Number: PRN1008-012 Start Date*: 2018-12-12
    Sponsor Name:Principia Biopharma
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus
    Medical condition: pemphigus vulgaris [PV] or pemphigus foliaceus [PF]
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    21.0 100000004858 10057054 Pemphigus foliaceous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing) GR (Completed) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004834-11 Sponsor Protocol Number: CR6086-2-02 Start Date*: 2017-07-06
    Sponsor Name:Rottapharm Biotech S.r.l.
    Full Title: A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 o...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BG (Completed) PL (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001966-10 Sponsor Protocol Number: 27937 Start Date*: 2009-05-04
    Sponsor Name:Merck Serono SA - Geneva
    Full Title: A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parki...
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) AT (Completed) GB (Prematurely Ended) EE (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000149-12 Sponsor Protocol Number: CXA30007 Start Date*: 2005-04-24
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase III, 12-week, Multicentre, Double-blind, Double-dummy, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group study to investigate the Efficacy and Safety of GW406381 1mg, 5m...
    Medical condition: Osteoarthritis of the Knee
    Disease: Version SOC Term Classification Code Term Level
    7.1 10023476 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) DK (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002230-30 Sponsor Protocol Number: D4260C00003 Start Date*: 2008-07-28
    Sponsor Name:AstraZeneca AB
    Full Title: A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236 as an Oral Tablet in Patients with Moderate to Severe...
    Medical condition: Chronic Obstructive Pulmonary Disease (study conducted in men or women, not of child bearing potential, aged 40 years or above).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SK (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-002488-88 Sponsor Protocol Number: GS-US-321-0105 Start Date*: 2013-07-29
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects w...
    Medical condition: Advanced Liver Fibrosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) DE (Prematurely Ended) GB (Prematurely Ended) ES (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002926-26 Sponsor Protocol Number: STM-042/K Start Date*: 2021-11-15
    Sponsor Name:Desitin Arzneimittel GmbH
    Full Title: Efficacy, Safety and Tolerability of 3 doses of Sulthiame in Patients with Obstructive Sleep Apnea. A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study
    Medical condition: Obstructive sleep apnea
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing) CZ (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003928-32 Sponsor Protocol Number: RD.06.SPR.203890 Start Date*: 2021-11-29
    Sponsor Name:Galderma S.A.
    Full Title: A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) BE (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005617-14 Sponsor Protocol Number: CLEE011Q12101 Start Date*: 2022-10-10
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblast...
    Medical condition: relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years old
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003586-35 Sponsor Protocol Number: 215336 Start Date*: 2022-01-25
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase I/II, observer-blind, randomised, placebo controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an HSV-targeted immunotherapy in healthy parti...
    Medical condition: Recurrent genital herpes
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10018150 Genital herpes PT
    21.1 10021881 - Infections and infestations 10073931 Genital herpes simplex PT
    24.0 10021881 - Infections and infestations 10084891 Anal herpes LLT
    20.1 10021881 - Infections and infestations 10054225 Anogenital herpes LLT
    20.1 10021881 - Infections and infestations 10018151 Genital herpes, unspecified LLT
    20.0 10021881 - Infections and infestations 10019937 Herpes genital LLT
    20.0 10021881 - Infections and infestations 10019938 Herpes genitalis LLT
    20.0 10021881 - Infections and infestations 10019997 Herpetic infection of penis LLT
    20.1 10021881 - Infections and infestations 10020003 Herpetic ulceration of vulva LLT
    20.1 10021881 - Infections and infestations 10020004 Herpetic vulvovaginitis LLT
    21.1 10021881 - Infections and infestations 10065050 Perianal herpes simplex LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005932-24 Sponsor Protocol Number: CBKM120F2202 Start Date*: 2012-07-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, phase II/III study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without ...
    Medical condition: This study will evaluate whether the addition of daily BKM120 to weekly paclitaxel is effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) CZ (Completed) ES (Temporarily Halted) NL (Completed) GB (Completed) BE (Completed) HU (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020744-35 Sponsor Protocol Number: D4300C00002 Start Date*: 2010-10-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Re...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) LV (Completed) LT (Completed) CZ (Completed) PT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006648-23 Sponsor Protocol Number: CIGE025A2437 Start Date*: 2008-11-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis
    Medical condition: Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    9.1 10000244 ABPA LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) IE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003925-26 Sponsor Protocol Number: 28156 Start Date*: 2008-01-24
    Sponsor Name:Merck Serono International S.A.
    Full Title: Estudio aleatorizado, multicéntrico, doble ciego, de dos ramas y controlado frente a placebo para evaluar la seguridad y la tolerabilidad, y para explorar el efecto neuroprotector de atacicept eva...
    Medical condition: Neuritis óptica Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) BE (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 281  282  283  284  285  286  287  288  289  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 17:31:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA